{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:33:04Z","timestamp":1795026784427,"version":"4.10.2"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.biopha.2025.118225","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T19:46:05Z","timestamp":1749066365000},"page":"118225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Modulating Wnt\/\u03b2-catenin pathway activity to enhance chemosensitivity in cholangiocarcinoma"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5134-1475","authenticated-orcid":false,"given":"Kevin","family":"Delgado-Calvo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7954-6705","authenticated-orcid":false,"given":"Luke","family":"Boulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6891-1554","authenticated-orcid":false,"given":"Oscar","family":"Briz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Rozyczko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Olaizola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose J.G.","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio I.R.","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7714-1691","authenticated-orcid":false,"given":"Elisa","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.biopha.2025.118225_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118225_bib2","article-title":"Cholangiocarcinoma across England: temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation","volume":"6","author":"Tataru","year":"2024","journal-title":"JHEP Rep."},{"issue":"2","key":"10.1016\/j.biopha.2025.118225_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.17998\/jlc.2024.08.07","article-title":"New systemic treatment options for advanced cholangiocarcinoma","volume":"24","author":"Zanuso","year":"2024","journal-title":"J. Liver Cancer"},{"issue":"14","key":"10.1016\/j.biopha.2025.118225_bib4","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.biopha.2025.118225_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"issue":"10391","key":"10.1016\/j.biopha.2025.118225_bib6","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2025.118225_bib7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118225_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clinre.2017.12.006","article-title":"Molecular bases of the poor response of liver cancer to chemotherapy","volume":"42","author":"Marin","year":"2018","journal-title":"Clin. Res Hepatol. Gastroenterol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118225_bib9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2174\/1389450116666150223121508","article-title":"Molecular Bases of Chemoresistance in Cholangiocarcinoma","volume":"18","author":"Marin","year":"2017","journal-title":"Curr. Drug Targets"},{"issue":"7","key":"10.1016\/j.biopha.2025.118225_bib10","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1136\/gutjnl-2016-312278","article-title":"Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers","volume":"66","author":"Carotenuto","year":"2017","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.biopha.2025.118225_bib11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s11626-024-00858-7","article-title":"Wnt\/beta-catenin signaling pathway in liver biology and tumorigenesis","volume":"60","author":"Matsumoto","year":"2024","journal-title":"Vitr. Cell Dev. Biol. Anim."},{"issue":"4","key":"10.1016\/j.biopha.2025.118225_bib12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1517\/14728222.2016.1098619","article-title":"Targeting the Wnt signaling pathway in colorectal cancer","volume":"20","author":"Sawa","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"issue":"4","key":"10.1016\/j.biopha.2025.118225_bib13","first-page":"973","article-title":"Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas","volume":"27","author":"Tokumoto","year":"2005","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.biopha.2025.118225_bib14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.humpath.2015.12.027","article-title":"Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma","volume":"52","author":"Talabnin","year":"2016","journal-title":"Hum. Pathol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118225_bib15","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1172\/JCI76452","article-title":"WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited","volume":"125","author":"Boulter","year":"2015","journal-title":"J. Clin. Invest"},{"issue":"2","key":"10.1016\/j.biopha.2025.118225_bib16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/mol.119.117978","article-title":"Wnt signaling and drug resistance in cancer","volume":"97","author":"Zhong","year":"2020","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2025.118225_bib17","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2020.11744","article-title":"Wnt\/beta\u2011catenin signaling: Causes and treatment targets of drug resistance in colorectal cancer (Review)","volume":"23","author":"Zhu","year":"2021","journal-title":"Mol. Med Rep."},{"key":"10.1016\/j.biopha.2025.118225_bib18","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9390878","article-title":"Role of Wnt\/beta-Catenin Signaling in the Chemoresistance Modulation of Colorectal Cancer","volume":"2020","author":"Yuan","year":"2020","journal-title":"Biomed. Res Int"},{"issue":"10","key":"10.1016\/j.biopha.2025.118225_bib19","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/cas.12223","article-title":"Inhibition of Wnt\/beta-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma","volume":"104","author":"Shen","year":"2013","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.biopha.2025.118225_bib20","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3748\/wjg.v21.i4.1148","article-title":"QX. beta-escin reverses multidrug resistance through inhibition of the GSK3beta\/beta-catenin pathway in cholangiocarcinoma","volume":"21","author":"Shen","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118225_bib21","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1021\/mp300028a","article-title":"No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors","volume":"9","author":"Martinez-Becerra","year":"2012","journal-title":"Mol. Pharm."},{"issue":"W1","key":"10.1016\/j.biopha.2025.118225_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.biopha.2025.118225_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252917","article-title":"Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells","volume":"16","author":"Kato","year":"2021","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.biopha.2025.118225_bib24","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/carcin\/bgh037","article-title":"Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma","volume":"25","author":"Yeh","year":"2004","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.biopha.2025.118225_bib25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3892\/mmr.2013.1516","article-title":"cDNA microarray pro fi ling of rat cholangiocarcinoma induced by thioacetamide","volume":"8","author":"Yeh","year":"2013","journal-title":"Mol. Med Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.118225_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0232-1513(84)80063-8","article-title":"Histogenesis of cholangiomas and cholangiocarcinomas in thioacetamide fed rats","volume":"26","author":"Praet","year":"1984","journal-title":"Exp. Pathol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118225_bib27","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20193353","article-title":"Wnt\/beta-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma","volume":"40","author":"Zhang","year":"2020","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.biopha.2025.118225_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150348","article-title":"Role of Wnt\/beta-catenin pathway in cancer drug resistance: Insights into molecular aspects of major solid tumors","volume":"729","author":"Samant","year":"2024","journal-title":"Biochem Biophys. Res Commun."},{"issue":"3","key":"10.1016\/j.biopha.2025.118225_bib29","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3892\/or.2013.2560","article-title":"Inhibition of Wnt signaling induces cell apoptosis and suppresses cell proliferation in cholangiocarcinoma cells","volume":"30","author":"Zhang","year":"2013","journal-title":"Oncol. Rep."},{"issue":"39","key":"10.1016\/j.biopha.2025.118225_bib30","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.2174\/1381612825666191112142943","article-title":"Wnt-beta-catenin signaling pathway, the achilles' heels of cancer multidrug resistance","volume":"25","author":"Ghandadi","year":"2019","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.biopha.2025.118225_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.canlet.2016.07.013","article-title":"Inhibition of the Wnt\/beta-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma","volume":"381","author":"Lin","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2025.118225_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1476-4598-10-16","article-title":"Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin","volume":"10","author":"Wei","year":"2011","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.118225_bib33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/labinvest.2015.150","article-title":"Targeting the Wnt\/beta-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974","volume":"96","author":"Boone","year":"2016","journal-title":"Lab Invest"},{"issue":"4","key":"10.1016\/j.biopha.2025.118225_bib34","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1074\/jbc.M007746200","article-title":"Molecular identification and characterization of novel human and mouse concentrative Na+\u2009-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib)","volume":"276","author":"Ritzel","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2025.118225_bib35","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.7150\/ijbs.83774","article-title":"UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT","volume":"20","author":"Du","year":"2024","journal-title":"Int J. Biol. Sci."},{"key":"10.1016\/j.biopha.2025.118225_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.125794","article-title":"Engineered multitargeting exosomes carrying miR-323a-3p for CRC therapy","volume":"247","author":"Pang","year":"2023","journal-title":"Int J. Biol. Macromol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118225_bib37","first-page":"1723","article-title":"Dihydrofolate reductase as a predictor for poor response to platinum-based chemotherapy in epithelial ovarian cancer","volume":"12","author":"Wang","year":"2019","journal-title":"Int J. Clin. Exp. Pathol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118225_bib38","doi-asserted-by":"crossref","first-page":"7313","DOI":"10.21037\/jtd-20-3185","article-title":"Plasma thymidylate synthase and dihydrofolate reductase mRNA levels as potential predictive biomarkers of pemetrexed sensitivity in patients with advanced non-small cell lung cancer","volume":"12","author":"Li","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.biopha.2025.118225_bib39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.dnarep.2017.01.002","article-title":"Differential role of base excision repair proteins in mediating cisplatin cytotoxicity","volume":"51","author":"Sawant","year":"2017","journal-title":"DNA Repair (Amst. )"},{"issue":"19","key":"10.1016\/j.biopha.2025.118225_bib40","doi-asserted-by":"crossref","first-page":"8430","DOI":"10.1093\/nar\/gkr563","article-title":"UNG-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation","volume":"39","author":"Pettersen","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.biopha.2025.118225_bib41","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3892\/ol.2023.14059","article-title":"p21 promotes gemcitabine tolerance in A549 cells by inhibiting DNA damage and altering the cell cycle","volume":"26","author":"Fu","year":"2023","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.biopha.2025.118225_bib42","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/1471-2407-11-399","article-title":"Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer","volume":"11","author":"Xia","year":"2011","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2025.118225_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10100373","article-title":"Cytoplasmic p21 Mediates 5-Fluorouracil Resistance by Inhibiting Pro-Apoptotic Chk2","volume":"10","author":"Maiuthed","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2025.118225_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110225","article-title":"Inhibition of Wnt\/beta-catenin pathway reverses multi-drug resistance and EMT in Oct4(+)\/Nanog(+) NSCLC cells","volume":"127","author":"Liu","year":"2020","journal-title":"Biomed. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2025.118225_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117097","article-title":"beta-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells","volume":"10","author":"Xu","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.biopha.2025.118225_bib46","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41575-022-00739-y","article-title":"Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance","volume":"20","author":"Calvisi","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118225_bib47","first-page":"4490","article-title":"The Wnt\/beta-catenin signaling pathway mechanism for pancreatic cancer chemoresistance in a three-dimensional cancer microenvironment","volume":"8","author":"Zhang","year":"2016","journal-title":"Am. J. Transl. Res"},{"issue":"2","key":"10.1016\/j.biopha.2025.118225_bib48","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/0192623315621192","article-title":"Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index <\u20091","volume":"44","author":"Zhong","year":"2016","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.biopha.2025.118225_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2020.100066","article-title":"Targeting Wnt\/\u03b2-catenin pathway for drug therapy","volume":"8","author":"Liu","year":"2020","journal-title":"Med. Drug Discov."},{"issue":"8","key":"10.1016\/j.biopha.2025.118225_bib50","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3390\/cells12081141","article-title":"Impact of Aberrant \u03b2-Catenin Pathway on Cholangiocarcinoma Heterogeneity","volume":"12","author":"Lozano","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.118225_bib51","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e15721","article-title":"Final results of a phase Ib dose-escalation study of PRI-724, a CBP\/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX","volume":"34","author":"Ko","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118225_bib52","article-title":"Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01\/nivolumab","author":"Park","year":"2024","journal-title":"medRxiv"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:56:05Z","timestamp":1758124565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225004196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":52,"alternative-id":["S0753332225004196"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118225","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modulating Wnt\/\u03b2-catenin pathway activity to enhance chemosensitivity in cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118225","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118225"}}